Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Leases Current Taxes Dividends payables Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Zhengye Biotechnology Holding (ZYBT) Other Accumulated Expenses (2024)

Zhengye Biotechnology Holding has reported Other Accumulated Expenses over the past 1 years, most recently at $20325.5 for Q4 2024.

Quarterly Other Accumulated Expenses changed N/A to $20325.5 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $20325.5 through Dec 2024, changed N/A year-over-year, with the annual reading at $20000.0 for FY2024, N/A changed from the prior year.
Other Accumulated Expenses was $20325.5 for Q4 2024 at Zhengye Biotechnology Holding.
Over five years, Other Accumulated Expenses peaked at $20325.5 in Q4 2024 and troughed at $20325.5 in Q4 2024.